Truist raised the firm’s price target on Edwards Lifesciences (EW) to $90 from $87 and keeps a Hold rating on the shares. The company delivered a solid Q3 revenue and earnings beat, marked by a return to 10% constant currency TAVR growth and a 2% TMTT beat while reflecting accelerating revenue growth, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target raised to $104 from $94 at Goldman Sachs
- Edwards Lifesciences price target raised to $90 from $85 at UBS
- Edwards Lifesciences price target raised to $84 from $81 at Canaccord
- Edwards Lifesciences upgraded to Outperform at Raymond James
- Edwards Lifesciences Reports Strong Earnings and Growth